Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Rhythm Pharmaceuticals, Inc. (RYTM)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rhythm Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Rhythm Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is RYTM. The reporting company's CIK number is 1649904.
The total value of stock buying since 2005 is $106,760,000.
The total value of stock sales since 2005 is $26,134,928.
The total value of stock option exercises since 2005 is $1,146,208.
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-01 | 0 | $0 | 0 | $0 | 33,072 | $151,800 |
| 2019-12 | 0 | $0 | 158,720 | $3,788,006 | 35,181 | $242,045 |
| 2019-11 | 0 | $0 | 557,857 | $12,473,951 | 0 | $0 |
| 2019-08 | 0 | $0 | 0 | $0 | 14,534 | $99,993 |
| 2019-07 | 0 | $0 | 0 | $0 | 17,500 | $103,225 |
| 2019-05 | 0 | $0 | 25,000 | $633,400 | 25,000 | $122,500 |
| 2019-03 | 0 | $0 | 19,578 | $588,827 | 0 | $0 |
| 2019-02 | 0 | $0 | 19,303 | $579,475 | 0 | $0 |
| 2019-01 | 0 | $0 | 26,756 | $803,586 | 3,000 | $20,640 |
| 2018-12 | 0 | $0 | 563 | $16,890 | 0 | $0 |
| 2018-11 | 0 | $0 | 54,500 | $1,639,740 | 28,200 | $171,540 |
| 2018-09 | 0 | $0 | 31,800 | $945,096 | 24,800 | $120,702 |
| 2018-08 | 0 | $0 | 0 | $0 | 14,534 | $99,993 |
| 2018-05 | 0 | $0 | 151,216 | $4,665,957 | 3,000 | $13,770 |
| 2017-10 | 6,280,000 | $106,760,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-01-08 | Gottesdiener Keith Michael (CEO & President) | Option Ex | 33,072 | 4.59 | 151,800 |
| 2019-12-27 | Desikan Nithya (Chief Commercial Officer) | Sale | 35,181 | 22.79 | 801,774 |
| 2019-12-27 | Desikan Nithya (Chief Commercial Officer) | Option Ex | 35,181 | 6.88 | 242,045 |
| 2019-12-12 | Foley Todd (Director) | Sale | 3,762 | 25.01 | 94,087 |
| 2019-12-11 | Foley Todd (Director) | Sale | 13,600 | 25.14 | 341,904 |
| 2019-12-10 | Foley Todd (Director) | Sale | 41,839 | 25.36 | 1,061,037 |
| 2019-12-09 | Foley Todd (Director) | Sale | 22,195 | 25.04 | 555,762 |
| 2019-12-03 | Foley Todd (Director) | Sale | 16,777 | 22.33 | 374,630 |
| 2019-12-02 | Foley Todd (Director) | Sale | 25,366 | 22.03 | 558,812 |
| 2019-11-29 | Foley Todd (Director) | Sale | 18,359 | 22.67 | 416,198 |
| 2019-11-27 | Foley Todd (Director) | Sale | 34,960 | 22.91 | 800,933 |
| 2019-11-26 | Foley Todd (Director) | Sale | 74,225 | 23.31 | 1,730,184 |
| 2019-11-25 | Foley Todd (Director) | Sale | 121,343 | 23.19 | 2,813,944 |
| 2019-11-22 | Foley Todd (Director) | Sale | 102,682 | 21.91 | 2,249,762 |
| 2019-11-21 | Foley Todd (Director) | Sale | 64,923 | 20.80 | 1,350,073 |
| 2019-11-20 | Foley Todd (Director) | Sale | 141,365 | 22.02 | 3,112,857 |
| 2019-08-12 | Desikan Nithya (Chief Commercial Officer) | Option Ex | 14,534 | 6.88 | 99,993 |
| 2019-07-16 | Gottesdiener Keith Michael (CEO and President) | Option Ex | 7,500 | 4.59 | 34,425 |
| 2019-07-11 | Smith Hunter C (Chief Financial Officer) | Option Ex | 10,000 | 6.88 | 68,800 |
| 2019-05-31 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 5,000 | 25.10 | 125,500 |
| 2019-05-31 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 5,000 | 4.59 | 22,950 |
| 2019-05-30 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 5,000 | 25.31 | 126,550 |
| 2019-05-30 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 5,000 | 4.59 | 22,950 |
| 2019-05-29 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 5,000 | 25.51 | 127,550 |
| 2019-05-29 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 5,000 | 4.59 | 22,950 |
| 2019-05-28 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 10,000 | 25.38 | 253,800 |
| 2019-05-28 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 10,000 | 5.37 | 53,650 |
| 2019-03-18 | Gottesdiener Keith Michael (CEO & President) | Sale | 2,329 | 30.27 | 70,498 |
| 2019-03-15 | Gottesdiener Keith Michael (CEO & President) | Sale | 7,961 | 30.04 | 239,148 |
| 2019-03-14 | Gottesdiener Keith Michael (CEO & President) | Sale | 1,506 | 30.05 | 45,255 |
| 2019-03-13 | Gottesdiener Keith Michael (CEO & President) | Sale | 7,782 | 30.06 | 233,926 |
| 2019-02-27 | Gottesdiener Keith Michael (CEO and President) | Sale | 1,814 | 30.01 | 54,438 |
| 2019-02-26 | Gottesdiener Keith Michael (CEO and President) | Sale | 635 | 30.13 | 19,132 |
| 2019-02-19 | Gottesdiener Keith Michael (CEO and President) | Sale | 918 | 30.05 | 27,585 |
| 2019-02-15 | Gottesdiener Keith Michael (CEO and President) | Sale | 12,002 | 30.02 | 360,300 |
| 2019-02-13 | Gottesdiener Keith Michael (CEO and President) | Sale | 3,934 | 30.00 | 118,020 |
| 2019-01-31 | Smith Hunter C (Chief Financial Officer) | Option Ex | 3,000 | 6.88 | 20,640 |
| 2019-01-23 | Gottesdiener Keith Michael (CEO and President) | Sale | 105 | 30.21 | 3,172 |
| 2019-01-22 | Gottesdiener Keith Michael (CEO and President) | Sale | 15,674 | 30.05 | 471,003 |
| 2019-01-18 | Gottesdiener Keith Michael (CEO & President) | Sale | 10,115 | 30.01 | 303,551 |
| 2019-01-16 | Gottesdiener Keith Michael (CEO & President) | Sale | 662 | 30.00 | 19,860 |
| 2019-01-16 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 200 | 30.00 | 6,000 |
| 2018-12-03 | Gottesdiener Keith Michael (CEO and President) | Sale | 563 | 30.00 | 16,890 |
| 2018-11-02 | Gottesdiener Keith Michael (CEO and President) | Sale | 16,500 | 30.08 | 496,320 |
| 2018-11-02 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 38,000 | 30.09 | 1,143,420 |
| 2018-11-02 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 28,200 | 6.08 | 171,540 |
| 2018-09-25 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Sale | 31,800 | 29.72 | 945,096 |
| 2018-09-25 | Van Der Ploeg Leonardus H.t. (Chief Scientific Officer) | Option Ex | 21,800 | 4.59 | 100,062 |
| 2018-09-05 | Smith Hunter C (Chief Financial Officer) | Option Ex | 3,000 | 6.88 | 20,640 |
| 2018-08-10 | Desikan Nithya (Chief Commercial Officer) | Option Ex | 14,534 | 6.88 | 99,993 |
| 2018-05-22 | Orbimed Capital Gp V Llc | Sale | 19,580 | 30.67 | 600,518 |
| 2018-05-21 | Orbimed Capital Gp V Llc | Sale | 62,500 | 31.01 | 1,938,125 |
| 2018-05-18 | Orbimed Capital Gp V Llc | Sale | 69,136 | 30.77 | 2,127,314 |
| 2018-05-09 | Gottesdiener Keith Michael (C.E.O. and President) | Option Ex | 3,000 | 4.59 | 13,770 |
| 2017-10-10 | Deerfield Private Design Fund Iii, L.p. | Buy | 355,000 | 17.00 | 6,035,000 |
| 2017-10-10 | Mpm Bioventures V Llc (10% Owner) | Buy | 100,000 | 17.00 | 1,700,000 |
| 2017-10-10 | Viswanathan Ravi (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Foley Todd (Director) | Buy | 100,000 | 17.00 | 1,700,000 |
| 2017-10-10 | Nea 13 Gp, Ltd (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Meeker David P (Director) | Buy | 25,000 | 17.00 | 425,000 |
| 2017-10-10 | Ipsen, S.a. (10% Owner) | Buy | 20,000 | 17.00 | 340,000 |
| 2017-10-10 | Baskett Forest (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Sandell Scott D (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Kerins Patrick J (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Mott David M (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Barrett M James (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Isaly Samuel D (10% Owner) | Buy | 355,000 | 17.00 | 6,035,000 |
| 2017-10-10 | Barris Peter J (10% Owner) | Buy | 550,000 | 17.00 | 9,350,000 |
| 2017-10-10 | Pfizer Inc (10% Owner) | Buy | 40,000 | 17.00 | 680,000 |
| 2017-10-05 | Baker Julian (Other) | Buy | 885,000 | 17.00 | 15,045,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of RYTM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rhythm Pharmaceuticals, Inc. (symbol RYTM, CIK number 1649904) see the Securities and Exchange Commission (SEC) website.